Plitidepsin

Drug Profile

Plitidepsin

Alternative Names: Aplidin; Aplidine; DDB; Dehydrodidemnin B

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmaMar
  • Class Antineoplastics; Depsipeptides
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Protein synthesis inhibitors; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Acute lymphoblastic leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma; Multiple myeloma; Peripheral T-cell lymphoma

Highest Development Phases

  • Preregistration Multiple myeloma
  • Phase II Non-Hodgkin's lymphoma; T cell lymphoma
  • No development reported Liposarcoma; Malignant melanoma; Myelofibrosis; Solid tumours
  • Discontinued Leukaemia; Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in France (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in USA (IV, Infusion)
  • 04 Oct 2017 Preregistration for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Switzerland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top